# OnCo record i-spy-2-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/i-spy-2-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "i-spy-2-2", "NCT01042379" ;
  schema:name "I-SPY 2.2"@en ;
  schema:alternateName "I-SPY2.2"@en, "ISPY 2.2"@en ;
  schema:description "I-SPY 2.2 takes the next step: instead of adding a new drug to the same chemotherapy for everyone, it assigns treatment by a tumour's predicted response type, checks with scans and biopsies whether the tumour is disappearing, and lets women who respond early skip further chemotherapy."@en ;
  schema:url <https://onco.cc/trials/i-spy-2-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01042379>, <https://www.ispytrials.org/i-spy-platform/i-spy2-2> ;
  onco:status "recruiting" ;
  onco:phase "platform" ;
  schema:startDate "2010-03-01" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-duocarmazine/> ;
  onco:companies <https://onco.cc/companies/quantum-leap-healthcare-collaborative/> ;
  onco:institutions <https://onco.cc/institutions/ucsf/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/seamless-adaptive/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/master-protocol/> ;
  onco:people <https://onco.cc/people/laura-esserman/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-i-spy-2-jama-oncol-2020/> .